Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$8.1MCash on Hand
20.2mo Cash Runway
Follow MIRA by emailGet an email when MIRA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MIRA, unsubscribe in one click. Privacy
📣 What MIRA Says Is Next
first half of 2027 · “Our strategy is to translate encouraging science into clinical evidence that can support meaningful treatment options for patients and create long-term value through future strategic partnerships.” Development Outlook MIRA continues advancing MIRA-55 through preclinical and IND-enabling activities, targeting an Investigational New Drug (IND) submission in the first half of 2027.”
Company press release, Nov 16, 2026 · SEC filing
first quarter of 2027 · “MIRA incorporated the FDA’s feedback into the protocol and is targeting site initiation in the first quarter of 2027, subject to completion of IRB review and other routine site activation requirements.”
Company press release, Sep 17, 2026 · SEC filing
first quarter of 2027 · “Subject to successful completion of the remaining IND-enabling studies, applicable regulatory requirements and other development considerations, the Company is targeting submission of an Investigational New Drug application for MIRA-55 to the U.S. Food and Drug Administration in the first quarter of 2027.”
Company press release, Sep 1, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Clinical trial MIRA reported new MIRA-55 receptor screening showing about 680-fold separation from mu opioid receptors and 540-fold from kappa opioid receptors, with no substantial COX-1 or COX-2 inhibition at tested concentrations. The company targets an IND submission in the first half of 2027. Form 8-K · SEC filing · Press release
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 28, 2026 ·
Clinical trial Reported initial pilot study results for oral SKNY-1 in diet-induced obese mice, with statistically significant reductions in body weight and fat mass versus vehicle. Weight loss occurred without a significant drop in food intake, and lean mass was preserved versus semaglutide, which showed significant lean-mass loss. Form 8-K · SEC filing · Press release
Oct 22, 2026 ·
Clinical trial Preclinical 21-day chronic inflammatory pain study found oral MIRA-55 significantly reduced pain hypersensitivity versus vehicle (p < 0.001), with effects comparable to celecoxib and no observed tolerance. IND submission still planned for Q1 2027. Form 8-K · SEC filing · Press release
Sep 17, 2026 ·
Regulatory Following FDA review and comments, MIRA's Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral neuropathy has been submitted for IRB review at a leading cancer research institution, with site initiation targeted for Q1 2027. Form 8-K · SEC filing · Press release
Sep 16, 2026 ·
Shareholder vote Shareholders re-elected five directors, ratified Salberg & Company, P.A. as auditor for fiscal 2026, and approved an adjournment proposal at the September 11, 2026 annual meeting. Each proposal passed with 26,499,076 shares present. Form 8-K · SEC filing
Sep 1, 2026 ·
Clinical trial MIRA reported positive 7-day rat and dog toxicology and toxicokinetic results for oral non-opioid MIRA-55 for inflammatory pain, used to inform dose selection. It targets an IND submission to the FDA in Q1 2027, subject to completing remaining studies. Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2026 · Phase 1 · Results Expected · Safety, Tolerability and Pharmacokinetics of Oral Ketamir-2 in Healthy Adult Subjects Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
MIRA holds $8.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.2M/quarter from operations,
an estimated runway of 20.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:58 · Elevated
Cash runway 17 months +18
ATM program on file since Dec 2025 +15
Shelf registration (S-3, Aug 2024) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Quarterly Report.10-Q, Nov 2026
Share count 42,022,087 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full MIRA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MIRA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.